Medical Condition News

RSS

ISIS-FXIRx reduces Factor XI activity without bleeding in healthy volunteers

Isis Pharmaceuticals, Inc. announced today positive results from a Phase 1 study with ISIS-FXIRx. The results demonstrated that treatment with ISIS-FXIRx produced dose-dependent statistically significant reductions of up to 78 percent in Factor XI activity.

13 Dec 2011

Scientists discover how intestinal tract influences B cells to prevent infection

Researchers at the University of Toronto have found an explanation for how the intestinal tract influences a key component of the immune system to prevent infection, offering a potential clue to the cause of autoimmune disorders like rheumatoid arthritis and multiple sclerosis.

13 Dec 2011

S*BIO announces results from pacritinib Phase 2 study on myelofibrosis

S*BIO Pte Ltd today announced that results from a Phase 2 study demonstrated that its JAK2 inhibitor pacritinib (SB1518) effectively reduced splenomegaly in myelofibrosis (MF) patients, with minimal impact on existing cytopenias providing an important therapeutic niche in the treatment of MF. Results were presented at the 53rd ASH Annual Meeting and Exposition in San Diego.

13 Dec 2011

WPI to develop smart phone app for foot ulcers, advanced diabetes

An interdisciplinary research team at Worcester Polytechnic Institute (WPI) has received a $1.2 million award from the National Science Foundation to develop a smart phone application that will help people with advanced diabetes and foot ulcers better manage their disease.

13 Dec 2011

Combination of bortezomib and panobinostat shows promise against advanced MM

When the targeted drug bortezomib stops working in patients with advanced multiple myeloma, the patients survive only an average of five months longer. But a phase 2 clinical trial has shown that pairing bortezomib with an experimental drug, panobinostat, may be a promising new treatment for such patients, Dana-Farber Cancer Institute researchers say.

13 Dec 2011

Scientists create antigenic myeloma peptide 'cocktail'

Scientists at Dana-Farber Cancer Institute have created a "cocktail" of immune-stimulating peptides they believe could provoke the body's defenses to attack multiple myeloma in its early "smoldering" phase and slow or prevent the blood cancer.

13 Dec 2011

Synta's ganetespib shows potent in vitro and in vivo activity against multiple breast cancer types

Synta Pharmaceuticals Corp. Ganetespib shows potent in vitro and in vivo activity against multiple types of breast cancer including HER2-positive, ER/PR positive, triple-negative, and inflammatory breast cancer according to results presented at the San Antonio Breast Cancer Symposium.

13 Dec 2011

Inaccurate blood pressure assessment may impact hypertension treatment decisions

Because some clinicians fail to stick to official recommendations for blood pressure monitoring, a number of patients are misclassified, which could have an impact on decisions about their treatment. According to Gretchen Ray and colleagues, from the University of New Mexico College of Pharmacy, when routine blood pressure monitoring in clinics is compared with measurements based on the latest guidelines, 93 percent of patients have different blood pressure readings.

13 Dec 2011

LTCRT participates in GPS study that seeks to personalize cancer care

The Lawson Translational Cancer Research Team (LTCRT) of the Lawson Health Research Institute is one of five groups participating in a new study that seeks to personalize cancer drug treatment.

13 Dec 2011

Single rooms in hospitals is not enough to prevent gastroenteritis

To offer patients single rooms in hospitals is not enough to prevent gastroenteritis. That is shown in a master thesis at Nordic School of Public Health NHV.

13 Dec 2011

NIH, Autism Speaks announce addition of AGRE as data federation site for NDAR

Autism Speaks - North America's largest autism science and advocacy organization - joins the National Institutes of Health (NIH) in announcing the addition of Autism Speaks Autism Genetic Resource Exchange (AGRE) as a data federation site for the National Database for Autism Research (NDAR). The addition of AGRE data will help create the largest multidisciplinary source of autism research data to date.

13 Dec 2011

PET scans can provide insight into process that causes aortic stenosis

Patients with life-threatening heart valve disease could be helped with alternative scanning techniques that provide greater insight into the condition.

13 Dec 2011

Consistent asthma medication use could prevent severe attacks

Researchers at Henry Ford Hospital have found that one-quarter of severe asthma attacks could be prevented if only patients consistently took their medication as prescribed.

13 Dec 2011

Celgene reports final results from REVLIMID plus VIDAZA phase II study on higher-risk MDS

Celgene International Sàrl, a subsidiary of Celgene Corporation, today reported final results from the phase II portion of a multi-center phase I/II study evaluating combination therapy with REVLIMID (lenalidomide) and VIDAZA (azacitidine) in patients with higher-risk myelodysplastic syndromes (MDS) not previously treated with either drug.

13 Dec 2011

Study: One kind of leukemia sometimes masquerades as another

One kind of leukemia sometimes masquerades as another, according to a study published online this week in the Journal of Experimental Medicine.

13 Dec 2011

KPT-SINE shows promise against CLL

An experimental drug that works by blocking the export of key control molecules from the nucleus of cancer cells shows promise as a treatment for chronic lymphocytic leukemia (CLL) and other incurable B-cell malignancies, according to a new study by researchers at the Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.

13 Dec 2011

Patients on contact precautions more likely to develop delirium during hospital stay

A new study finds that patients who are moved into isolation during a hospital stay are nearly twice as likely to develop delirium, a potentially dangerous change in mental status that often affects hospital patients. Patients who began their stay in isolation were not at increased risk.

13 Dec 2011

Low-volume high-intensity exercise training may help treat type 2 diabetes

Regular exercise has proven benefits in preventing and treating type 2 diabetes, but many patients find it tough to meet the American Diabetes Association guidelines of 150 minutes of moderate to vigorous exercise a week.

13 Dec 2011

Plexxikon announces scientific findings from PLX3397 preclinical studies on AML

Plexxikon Inc., a member of Daiichi Sankyo Group, today announced scientific findings from preclinical studies showing that treatment with a novel oral agent, PLX3397, selectively inhibited key cancer-driving Flt3 mutations that occur in 20-30 percent of acute myeloid leukemia (AML) patients.

13 Dec 2011